A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.
Clinical trial NCT00423566 · COMPLETED
Trial details
- NCT number
- NCT00423566
- Sponsor
- University of Oxford
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2002-09-01
- Enrollment
- 14
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.